Enanta Pharmaceuticals (ENTA) Receivables (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Receivables came in at $7.8 million in Q1 2026, up 14.97% YoY from $6.8 million in Q1 2025, and down 8.05% on a QoQ basis from $8.5 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Receivables (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Receivables data on file, last reported at $7.8 million in Q1 2026.
- Quarterly Receivables rose 14.97% year-over-year to $7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.8 million (up 14.97% YoY) and the FY2025 annual result came in at $6.9 million, up 3.55% from the prior year.
- Receivables retreated to $7.8 million in Q1 2026, from $8.5 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $22.6 million in Q4 2022 to a low of $6.6 million in Q3 2024.
- A 5-year average of $12.0 million and a median of $8.3 million in 2025 frame the typical range for Receivables.
- Annual changes were most pronounced in 2023 — Receivables slumped 63.81% — and 2026, when it gained 14.97%.
- Tracing ENTA's Receivables over 5 years: stood at $22.6 million in 2022, then tumbled by 63.81% to $8.2 million in 2023, then dropped by 5.57% to $7.7 million in 2024, then rose by 10.04% to $8.5 million in 2025, then retreated by 8.05% to $7.8 million in 2026.
- The last three Receivables figures came in at $7.8 million (Q1 2026), $8.5 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 6.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.53 Mn |
| Mar 31, 2026 | 7.81 Mn |
| Dec 31, 2025 | 8.49 Mn |
| Sep 30, 2025 | 6.88 Mn |
| Jun 30, 2025 | 8.33 Mn |
| Mar 31, 2025 | 6.79 Mn |
| Dec 31, 2024 | 7.72 Mn |
| Sep 30, 2024 | 6.65 Mn |
| Jun 30, 2024 | 8.18 Mn |
| Mar 31, 2024 | 7.76 Mn |
| Dec 31, 2023 | 8.17 Mn |
| Sep 30, 2023 | 8.61 Mn |
| Jun 30, 2023 | 18.89 Mn |
| Mar 31, 2023 | 17.80 Mn |
| Dec 31, 2022 | 22.59 Mn |
| Sep 30, 2022 | 20.32 Mn |
| Jun 30, 2022 | 19.48 Mn |
| Mar 31, 2022 | 18.72 Mn |
| Dec 31, 2021 | 27.65 Mn |
| Sep 30, 2021 | 23.58 Mn |